CTLA4 and cutaneous melanoma: According to ex vivo study of patients with stage IV cutaneous melanoma, CD14−CD16+ non-classical monocytes kill regulatory T lymphocytes (Tregs) by assisting ipilimumab, anti-cytotoxic T lymphocyte associated antigen 4 (CTLA4) monoclonal antibody, -mediated ADCC (antibody-dependent cell-mediated cytotoxicity) (62).